The particulars: injection-site erythema · twelve · liraglutide.
I would like to understand the steps well enough to explain them to someone else.
I have access to a refrigerator with a logger and a freezer without one, which may be relevant.
Which parts of this are load-bearing and which parts are habit?
Week 12 is day 84: on a four-week ladder that is week 4 of dose step 3, and — at the seven-day half-life this class runs on — 12 half-lives in. Steady state is about five half-lives, so day 35 is where the concentration stops climbing on its own. Day 84 is 7 weeks past it, which means the level is no longer the variable. That distinction is most of the question: at week 4 of a step, an effect that is still accumulating is indistinguishable from one that is not resolving unless you know which side of day 35 you are on. Local erythema is a site-and-technique observation before it is a drug observation. It should track where and how you injected rather than how many weeks you have been injecting, so the useful record is a rotation log rather than a week count. Dose decisions are made under supervision, and nothing here is medical advice.
Answer first: a small area of redness, itching or a firm lump lasting a few days is a local reaction and is common; spreading redness with warmth, pain and fever is not, and needs assessment.
Immediate stinging is usually the injectate: cold solution, a preservative, or a hypotonic diluent. Room-temperature solution injected slowly removes most of it.
| Feature | Local reaction | Sterile abscess | Cellulitis |
|---|---|---|---|
| Onset | Hours to 2 days | Days | 1–4 days, progressive |
| Warmth | Absent or minimal | Mild | Marked |
| Expansion | Static or shrinking | Slow | Expanding |
| Texture | Firm, flat or raised | Fluctuant | Diffuse, indurated |
| Systemic features | None | None | Fever, malaise possible |
| Action | Observe, rotate site | Clinical review | Same-day clinical review |
The relevant detail is that features that point towards infection rather than reaction: expanding redness beyond a few centimetres, increasing rather than decreasing pain after forty-eight hours, warmth, fluctuance, fever or malaise.
Injection-site reactions are reported in the trial programmes for this class at low single-figure to low double-figure percentages depending on agent and formulation.
Absence of infection cannot be established from a description on a forum, which is why the discriminating features matter more than reassurance.
Improving after forty-eight hours is reassuring. Worsening is not.
HPLC purity, identity confirmation and quantified content on the vial you actually hold. Reports arrive with the chromatogram attached, not just a number.
Submit a sampleFounded 1998. ISO 9001 and cGMP certified, 1,500+ staff and 200+ patents. The synthesis house behind a great many of the vials that get sent out for testing - batch-specific documentation with every order.
Visit GL BiochemAsk PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.